Quotient Clinical Acquires Co-Formulate Limited

December 16, 2015
Pharmaceutical Technology Editors

PTSM: Pharmaceutical Technology Sourcing and Management

PTSM: Pharmaceutical Technology Sourcing and Management-01-06-2016, Volume 12, Issue 1

Quotient Clinical announced on Dec. 16, 2015 that is has acquired Co-Formulate Limited.

On Dec. 16, 2015 Quotient Clinical announced that it has acquired contract development company Co-Formulate Limited.

Quotient Clinical is a drug-development services company. The company created a Translational Pharmaceutics platform, which integrates formulation development, GMP manufacturing, and clinical testing. Co-Formulate Limited is a contract product development company that provides a range of comprehensive development, analytical, and regulatory services.

Quotient Clinical’s acquisition of Co-Formulate extends Quotient’s existing pharmaceutical development capabilities across solid, semisolid and liquid formulations. Co-Formulate is based adjacent to Quotient’s new GMP facility in Nottingham, UK, which will enable integration of formulation development and GMP manufacturing services. 

Financial terms of the transaction were not disclosed. 

Source: Quotient Clinical